NCT07085507View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT7208 in Healthy Participants and MS Patients

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

October 30, 2026

Study Completion Date

December 31, 2027

Conditions

Multiple Sclerosis

Interventions

DRUG

VT7208

a small synthetic molecule capsule, oral

DRUG

Placebo

capsule, oral

Trial Locations (1)

5000

RECRUITING

CMAX, Adelaide

All Listed Sponsors

collaborator

Vidya Therapeutics Australia Pty Ltd

UNKNOWN

lead

Vidya Therapeutics Inc

INDUSTRY

NCT07085507 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT7208 in Healthy Participants and MS Patients | Biotech Hunter | Biotech Hunter